IL36346A - Method and preparation containing an imidazoline derivative for treatment of anaplasmosis in cattle - Google Patents

Method and preparation containing an imidazoline derivative for treatment of anaplasmosis in cattle

Info

Publication number: IL36346A
Authority: IL; Israel
Prior art keywords: administration; dosage; package; treatment; active
Prior art date: 1970-03-13

Application number

IL36346A

Other languages

English (en)

Other versions

IL36346A0 (en

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1970-03-13

Filing date

1971-03-04

Publication date

1974-11-29

1971-03-04 Application filed by Wellcome Found filed Critical Wellcome Found

1971-05-26 Publication of IL36346A0 publication Critical patent/IL36346A0/xx

1974-11-29 Publication of IL36346A publication Critical patent/IL36346A/en

Links

238000011282 treatment Methods 0.000 title claims description 67
238000000034 method Methods 0.000 title claims description 20
208000011804 anaplasmosis in cattle Diseases 0.000 title description 8
238000002360 preparation method Methods 0.000 title description 5
150000002462 imidazolines Chemical class 0.000 title 1
241001465754 Metazoa Species 0.000 claims description 52
244000309466 calf Species 0.000 claims description 35
208000006730 anaplasmosis Diseases 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 21
241000283690 Bos taurus Species 0.000 claims description 18
230000037396 body weight Effects 0.000 claims description 15
208000015181 infectious disease Diseases 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 11
GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 claims description 10
230000036039 immunity Effects 0.000 claims description 9
241000606646 Anaplasma Species 0.000 claims description 8
238000007918 intramuscular administration Methods 0.000 claims description 7
239000000839 emulsion Substances 0.000 claims description 5
238000004659 sterilization and disinfection Methods 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 4
230000003442 weekly effect Effects 0.000 claims description 3
239000008346 aqueous phase Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
239000002480 mineral oil Substances 0.000 claims description 2
235000010446 mineral oil Nutrition 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
150000001734 carboxylic acid salts Chemical class 0.000 claims 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 claims 1
230000003387 muscular Effects 0.000 claims 1
SCEVFJUWLLRELN-UHFFFAOYSA-N imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 24
229960004683 imidocarb Drugs 0.000 description 24
238000007920 subcutaneous administration Methods 0.000 description 13
241000606665 Anaplasma marginale Species 0.000 description 12
230000009467 reduction Effects 0.000 description 11
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
-1 2-imidazolin-2-yl Chemical group 0.000 description 4
241000223104 Trypanosoma Species 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000001154 acute effect Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
208000007502 anemia Diseases 0.000 description 3
230000007503 antigenic stimulation Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000007972 injectable composition Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000008174 sterile solution Substances 0.000 description 3
241000238876 Acari Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
230000008029 eradication Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
MLRXMTYSQKIKAK-UHFFFAOYSA-N 1,3-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea;hydron;dichloride Chemical compound Cl.Cl.C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 MLRXMTYSQKIKAK-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
241000606643 Anaplasma centrale Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
CRPUJAZIXJMDBK-UHFFFAOYSA-N Toxaphene Natural products C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
230000000895 acaricidal effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960004475 chlortetracycline Drugs 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004283 imidazolin-2-yl group Chemical group [H]N1C(*)=NC([H])([H])C1([H])[H] 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000005649 metathesis reaction Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940063650 terramycin Drugs 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
OEJNXTAZZBRGDN-UHFFFAOYSA-N toxaphene Chemical compound ClC1C(Cl)C2(Cl)C(CCl)(CCl)C(=C)C1(Cl)C2(Cl)Cl OEJNXTAZZBRGDN-UHFFFAOYSA-N 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000001018 virulence Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL36346A 1970-03-13 1971-03-04 Method and preparation containing an imidazoline derivative for treatment of anaplasmosis in cattle IL36346A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB1234770A GB1358979A (en)	1970-03-13	1970-03-13	Treatment of anaplasmosis in cattle

Publications (2)

Publication Number	Publication Date
IL36346A0 IL36346A0 (en)	1971-05-26
IL36346A true IL36346A (en)	1974-11-29

Family

ID=10002851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL36346A IL36346A (en)	1970-03-13	1971-03-04	Method and preparation containing an imidazoline derivative for treatment of anaplasmosis in cattle

Country Status (6)

Country	Link
US (1)	US3795737A (fr)
GB (1)	GB1358979A (fr)
IL (1)	IL36346A (fr)
OA (1)	OA03694A (fr)
ZA (1)	ZA711291B (fr)
ZM (1)	ZM2771A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4213818B1 (fr) *	2020-09-14	2026-03-11	Bimeda AMEA Limited	Formulation vétérinaire injectable optimisée

1970
- 1970-03-13 GB GB1234770A patent/GB1358979A/en not_active Expired
1971
- 1971-03-01 ZA ZA711291A patent/ZA711291B/xx unknown
- 1971-03-04 IL IL36346A patent/IL36346A/en unknown
- 1971-03-08 ZM ZM27/71A patent/ZM2771A1/xx unknown
- 1971-03-10 US US00123033A patent/US3795737A/en not_active Expired - Lifetime
- 1971-03-13 OA OA54197A patent/OA03694A/fr unknown

Also Published As

Publication number	Publication date
US3795737A (en)	1974-03-05
GB1358979A (en)	1974-07-03
IL36346A0 (en)	1971-05-26
OA03694A (fr)	1971-12-24
ZA711291B (en)	1971-11-24
ZM2771A1 (en)	1972-10-23

Publication	Publication Date	Title
EP0139535B1 (fr)	1990-12-27	Compositions pour combattre la toxaemie
Norden et al.	1986	Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus
US4835140A (en)	1989-05-30	Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine
Long et al.	1939	Mode of action, clinical use and toxic manifestations of sulfanilamide: further observations
Daikos et al.	1973	Trimethoprim-sulfamethoxazole in brucellosis
Miller et al.	1946	Streptomycin resistance of gonococci and meningococci
US4078088A (en)	1978-03-07	Method of treating Theileriosis
Whittle et al.	1973	Trial of chloramphenicol for meningitis in northern savanna of Africa
Sabin et al.	1940	The therapeutic effectiveness of a practically nontoxic new compound (calcium aurothiomalate) in experimental, proliferative, chronic arthritis of mice
EP0188499A1 (fr)	1986-07-30	Preparation antivirale et son procede de production
IL36346A (en)	1974-11-29	Method and preparation containing an imidazoline derivative for treatment of anaplasmosis in cattle
Chang	1975	Mechanism of action of colchicine. II. Effects of colchicine and its analogs on phagocytosis and chemotaxis in vitro.
Nelson et al.	1975	Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children
Vlasveld et al.	1991	Treatment with deferoxamine: a real risk factor for mucormycosis
WOOD JR et al.	1939	Observations upon the experimental and clinical use of sulfapyridine. III. The mechanism of recovery from pneumococcal pneumonia in patients treated with sulfapyridine
Wong et al.	1974	Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol
US3592915A (en)	1971-07-13	Treatment of anaplasmosis in animals
Forbes et al.	1973	Trimethoprim-sulfamethoxazole in recurrent urinary tract infection in children
Fitzwilliam et al.	1976	Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid
Lukehart et al.	1984	Efficacy of aztreonam in treatment of experimental syphilis in rabbits
CA1242147A (fr)	1988-09-20	Methode de traitement des infections a virus
Poth et al.	1942	A preliminary report on the treatment of bacillary dysentery with succinyl sulfathiazole
Rollo et al.	1948	Acquired Paludrine-Resistance in Plasmodium Gallinaceum: Ii—Failure to Produce Such Resistance by Prolonged Treatment of Latent Infections
Lawrence et al.	1943	In vitro effects of quinine, atabrine and substituted acridine compounds upon Gram negative bacteria
BARBOUR et al.	1939	Experience with sulfanilamide in treatment of gonorrheal ophthalmia